<DOC>
	<DOCNO>NCT00066391</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy irinotecan cisplatin use different way stop tumor cell divide stop grow die . Combining irinotecan cisplatin may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine irinotecan cisplatin treat patient locally advance metastatic penile cancer .</brief_summary>
	<brief_title>Irinotecan Cisplatin Treating Patients With Locally Advanced Metastatic Penile Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine anticancer activity irinotecan cisplatin patient locally advance metastatic penile cancer . - Determine objective response rate duration response patient treat regimen . - Determine acute side effect regimen patient . OUTLINE : This open-label , nonrandomized , multicenter study . Patients receive irinotecan IV 30 minute day 1 , 8 , 15 cisplatin IV 1-3 hour day 1 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Patients undergo local treatment receive 8 course . Patients plan undergo surgery receive 4 course . Patients follow every 8 week disease progression every 3 month thereafter . PROJECTED ACCRUAL : A total 13-28 patient accrue study .</detailed_description>
	<mesh_term>Penile Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm penile squamous cell carcinoma Locally advance metastatic disease T3 , N12 OR T4 , N3 , M1 Measurable disease outside previously irradiated field No clinical sign brain metastasis PATIENT CHARACTERISTICS : Age 75 Performance status WHO 02 Life expectancy Not specify Hematopoietic Absolute neutrophil count least 2,000/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin great 1.5 time upper limit normal ( ULN ) Alkaline phosphatase great 2.5 time ULN ( 5 time ULN presence liver metastasis ) Transaminases great 2.5 time ULN ( 5 time ULN presence liver metastasis ) Renal Glomerular filtration rate least 60 mL/min Gastrointestinal No chronic diarrhea No unresolved bowel obstruction No chronic inflammatory bowel disease ( e.g. , Crohn 's disease ulcerative colitis ) Other No prior concurrent malignancy except adequately treated skin cancer No psychological , familial , sociological , geographical condition would preclude study compliance followup PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy Endocrine therapy Not specify Radiotherapy See Disease Characteristics More 4 week since prior radiotherapy No concurrent radiotherapy pain control Surgery Not specify Other No concurrent experimental anticancer therapy</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>penile squamous cell carcinoma</keyword>
	<keyword>stage III penile cancer</keyword>
	<keyword>stage IV penile cancer</keyword>
</DOC>